GU NURSES CONNECT

Journey through a patient's mCRPC treatment program with urologist Neal Shore. 👉 https://ow.ly/rTCX50QABXL In this animated video you'll hear about the importance of genetic testing when treating prostate cancer with PARP inhibitor monotherapy. The video is designed to make learning simple and engaging. You will learn about: > Efficacy and safety profiles of PARP inhibitors for prostate cancer > The role of genetic testing and how to use it to assess HRRm status and influence treatment decision-making > Data from key PARPi mCRPC studies and the clinical implication of this data ZERO Prostate Cancer endorsed #MedEd #MedicalEducation #Oncology #prostatecancer

🚨 The latest GU oncology data from #ESMO24 🚨 Dr Ray Manneh Kopp shares his insights into new renal, bladder, and prostate cancer data presented at ESMO 2024. Watch his video update 📺👇 https://lnkd.in/eCdpCs5g Dr Ray Manneh Kopp reviews data from the following trials: ➡️ A randomised multicenter open label phase 3 trial comparing enzalutamide vs a combination of Radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone mCRPC: First results of EORTC-GUCG 1333/PEACE-3 Gillessen S, et al. (Abstract LBA1) ➡️ A randomised phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA) Powles T, et al. (Abstract LBA5) ➡️ Tivozanib–nivolumab vs tivozanib monotherapy in patients with RCC following 1 or 2 prior therapies including an immune checkpoint inhibitor – Results of the phase 3 TiNivo-2 Study Choueiri T, et al. (Abstract LBA73) #MedicalEducation #oncology

Don't forget to catch-up on the latest GU cancer data from ESMO 2024 from our physician partner group GU CONNECT...

See this insightful video update on the latest data from ESMO 2024 on GU cancer from our physician partner group GU CONNECT....

How can you best manage long-term durable response in individuals with advanced RCC? Find out as you make treatment decisions for a 50 year old man with ccRCC in this on-demand and interactive case study with expert Prof. Michael Staehler . Along the way you'll also learn about the efficacy and safety profiles of various treatment options, determine suitable first-line options, how to determine progression and timing for switching to second-line therapy . Key questions and resources are provided along the way. Jump in here: https://ow.ly/k5nB50SuUTS This program is endorsed by Urobel vzw #IndependentMedEd #FREEMedicalEducation #MedicalEducation #Oncology #RCC This educational programme is supported by an Independent Medical Education Grant from Eisai Europe Limited.

👉Real-world data support using 177Lu-PSMA in patients who previously received Ra-223. How can we apply recent data to treatment sequencing in bone-dominant mCRPC? It's important that GU oncology nurses are up to date with the current data on radiopharmaceutical treatments for prostate cancer so they can inform and support their patients. In this clinical video update, Uro-oncology Clinical Nurse Specialist Janet Forgenie tells us more about the considerations for treatment selection in clinical practice to minimise the impact on patients' lives. https://ow.ly/uOSq50QjaRL #Oncology #MedEd This programme is supported by an Independent Medical Education Grant from Bayer.

Check out this Experts Knowledge Share programme from our sister group Precision Oncology CONNECT Learn about the challenges and considerations of biomarker testing for #prostatecancer and #lungcancer with experts Fernando López-Ríos, Alicia Morgans and Herbert Loong. #MedEd #oncology

'Patients are more likely to adhere to a treatment plan if they understand their choices and the implications of each treatment.' This ⬆️ is just one of the key clinical takeaways from an educational podcast from GU specialists Assoc. Prof. Alicia Morgans and Nurse Practitioner Brenda Martone. The experts discuss shared decision-making for patients with non-metastatic castration-resistant #prostatecancer (nmCRPC) and treatment considerations to maintain quality of life. 🎧Listen to the podcast, download the transcript and get the rest of the key clinical takeaways on our website 👉 https://ow.ly/UWMY50QjHC8 Or listen wherever you get your podcasts 👇 🎧Spotify >> https://ow.ly/jYV650QjHE1 🎧Google >> https://ow.ly/FM5J50QjHE9 🎧Apple >> https://ow.ly/Mo9h50QjHL4 #Oncology #MedEd This educational programme is supported by an Independent Educational Grant from AstraZeneca.

❗#ASCO24 update❗ Medical experts joined us at ASCO 2024 to review the latest data on lung cancer, HCC, breast cancer, and upper GI cancer. Watch the 12-minute summary video on YouTube 📺 https://ow.ly/UNxw50SaIRY Or choose your update update according to tumour type: 💠Lung: https://ow.ly/VSQQ50SaJfI (from Prof. Mark Socinski) 💠HCC: https://ow.ly/1OSu50SaJj7 (from Prof. Dr Peter R Galle) 💠Breast: https://ow.ly/IaGr50SaIFj (from Prof. Shaheenah Dawood) 💠 Upper GI*: https://ow.ly/lGI250SaIFh (from Drs Lizzy Smyth and Samuel Klempner) #MedicalEducation #oncology *Upper GI update supported by an Independent Medical Education Grant from Bayer

We are excited for the upcoming #ASCO24 congress. Here are a few abstracts in Prostate Oncology that we think may be of particular interest...